List of Excipients in Branded Drug AMLODIPINE, VALSARTAN, HYDROCHLOROTHIAZIDE

Generic Drugs Containing AMLODIPINE, VALSARTAN, HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Par Pharmaceutical Inc	amlodipine besylate valsartan hydrochlorothiazide	49884-172	CELLULOSE, MICROCRYSTALLINE
Par Pharmaceutical Inc	amlodipine besylate valsartan hydrochlorothiazide	49884-172	CROSPOVIDONE
Par Pharmaceutical Inc	amlodipine besylate valsartan hydrochlorothiazide	49884-172	FD&C YELLOW NO. 5
Par Pharmaceutical Inc	amlodipine besylate valsartan hydrochlorothiazide	49884-172	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in AMLODIPINE, VALSARTAN, HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
3	CROSPOVIDONE
1	FD&C YELLOW NO. 5
1	FERRIC OXIDE YELLOW

Amlodipine, Valsartan and Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Amlodipine/valsartan/hydrochlorothiazide is a mature fixed-dose antihypertensive combination with limited active-ingredient patent protection in major markets. The strongest commercial opportunities are in bioequivalent generics, regional dosage-form optimization, manufacturing efficiency, supply-chain resilience and differentiated presentations rather than new chemical-entity exclusivity. Excipients can improve tablet robustness, dissolution consistency, swallowability, stability and cost, but they generally cannot create meaningful market exclusivity without a defensible formulation or device claim.

The reference product is Exforge HCT, marketed by Novartis. It combines the calcium-channel blocker amlodipine, the angiotensin II receptor blocker valsartan and the thiazide diuretic hydrochlorothiazide. The product is indicated for hypertension in patients requiring combination therapy and is available in multiple strength combinations under the U.S. product label [1].

What is the formulation profile of amlodipine, valsartan and hydrochlorothiazide?

The combination contains three pharmacologically different active pharmaceutical ingredients with materially different formulation properties.

Component	Functional class	Key formulation issue
Amlodipine besylate	Dihydropyridine calcium-channel blocker	Low-dose API; content uniformity and segregation control
Valsartan	Angiotensin II receptor blocker	Relatively high-dose API; poor aqueous solubility and dissolution sensitivity
Hydrochlorothiazide	Thiazide diuretic	Low-to-moderate dose; content uniformity and moisture control
Final product	Immediate-release tablet	Multi-API compatibility, dissolution and physical stability

Valsartan is the principal formulation driver. Its low solubility can make dissolution performance sensitive to particle size, wetting, granulation conditions, compression force and excipient selection. Amlodipine and hydrochlorothiazide are present at lower quantities, increasing the risk that segregation or inadequate blending will affect dose uniformity.

A practical formulation must accommodate:

• High-dose valsartan loading.
• Low-dose amlodipine distribution.
• Uniform hydrochlorothiazide dispersion.
• Rapid and reproducible release of all three APIs.
• Adequate tablet hardness without excessive disintegration time.
• Low moisture exposure.
• Compatibility with automated, high-speed tableting.

The reference product uses conventional immediate-release tablet technology. Public labeling identifies common excipient classes including microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, talc and colorants, although the exact composition can vary by strength and market [1].

What excipients are suitable for this triple antihypertensive tablet?

The most commercially relevant excipient platform is a direct-compression or dry-granulation system built around microcrystalline cellulose, a superdisintegrant, a glidant and a lubricant.

Fillers and compression aids

Microcrystalline cellulose is a strong baseline excipient because it supports compactibility, dilution potential and rapid tablet disintegration. It is suitable where valsartan constitutes a large fraction of tablet mass.

Anhydrous dibasic calcium phosphate can improve density, flow and mechanical strength. Its use requires careful compatibility evaluation because inorganic fillers can alter microenvironmental pH and may affect dissolution behavior.

Mannitol can improve mouthfeel and reduce tablet density, but it is more expensive than standard cellulose-based fillers. It is more attractive for orally disintegrating or chewable presentations than for a conventional swallow tablet.

Lactose may support low-cost formulation development, but its suitability depends on API compatibility, moisture exposure and the selected manufacturing process. A lactose-free formulation can simplify global labeling and reduce concerns relating to dairy-derived excipients.

Disintegrants

Crospovidone is well suited to immediate-release tablets containing poorly soluble valsartan because it promotes capillary wicking and rapid tablet breakup. Croscarmellose sodium is another viable option, particularly when higher swelling capacity is desirable.

Sodium starch glycolate can deliver rapid disintegration but may produce excessive swelling or variable performance if overused. The final selection should be based on dissolution across physiological pH conditions, not only on disintegration time.

Glidants and lubricants

Colloidal silicon dioxide can improve powder flow and reduce die-fill variability. This is especially important when low-dose amlodipine is blended with a high-dose valsartan matrix.

Magnesium stearate is an effective lubricant but can retard wetting and dissolution if over-lubrication occurs. Mixing time, lubricant concentration and shear history should be controlled as critical process parameters.

Sodium stearyl fumarate can be evaluated as an alternative lubricant where magnesium stearate causes dissolution loss or excessive hydrophobicity. It may also support a more robust formulation in high-speed compression.

Film coating systems

A film coat can protect the tablet from moisture, mask taste and improve appearance. Hypromellose-based systems are widely applicable. Polyethylene glycol acts as a plasticizer, while titanium dioxide and iron oxides provide color.

A low-weight, aqueous film coat is generally preferable for cost and throughput. A moisture-barrier coating may be justified if stability studies show sensitivity of valsartan or the finished product to humidity.

How should manufacturers design the excipient strategy?

The formulation strategy should begin with a risk-ranked assessment of each API rather than treating the product as a standard three-component blend.

Use staged blending for low-dose amlodipine

Amlodipine should be pre-blended with a portion of the filler or a carrier excipient before incorporation into the main blend. Geometric dilution reduces segregation and improves content uniformity.

The process should control:

• API particle-size distribution.
• Bulk and tapped density.
• Blend time.
• Order of addition.
• Transfer distance.
• Hopper residence time.
• Sampling locations.

Continuous manufacturing may offer better control of segregation and residence time, but it requires robust feeding technology and validated process monitoring.

Protect valsartan dissolution

Particle-size control, wetting agents and disintegrant selection are the main levers for valsartan dissolution. A surfactant such as sodium lauryl sulfate may improve wetting, but it can create tolerability, taste and regulatory concerns. Its use should be justified by dissolution and stability data.

A solid dispersion or amorphous formulation can improve valsartan solubility, but that approach increases development complexity and may create new stability risks. For a conventional generic, a simpler crystalline API and immediate-release matrix usually provide a better cost-to-benefit profile.

Control moisture and compression force

Moisture can affect powder flow, tablet hardness, disintegration and valsartan dissolution. Dry granulation may be preferable where wet granulation creates chemical or physical stability concerns.

Excessive compression force can produce hard tablets with slow disintegration. The development target should be a narrow operating range that maintains mechanical strength while preserving rapid dissolution.

What formulations are protected by patents?

The principal patent risk historically related to the triple combination itself and associated dosage regimens, not to the use of ordinary excipients such as microcrystalline cellulose or magnesium stearate.

Novartis developed Exforge HCT as an extension of the Exforge amlodipine/valsartan franchise. U.S. patent records include patents directed to combinations of amlodipine, valsartan and hydrochlorothiazide, including U.S. Patent No. 7,585,865 [2]. The relevant protection was filed years before the product’s 2009 U.S. approval and was subject to statutory patent-term rules and any applicable pediatric extension.

A formulation developer should distinguish among:

1. Composition-of-matter claims covering the active combination.
2. Fixed-dose combination claims covering specific ratios or strengths.
3. Method-of-use claims covering treatment of hypertension.
4. Formulation claims covering excipient systems, release profiles or solid-state forms.
5. Process claims covering granulation, blending or tablet manufacture.

Most routine excipient substitutions will not create a blocking patent position. They can still generate freedom-to-operate issues if a patent claims a broad pharmaceutical composition or a specific excipient combination.

What is the Orange Book status of Exforge HCT?

Exforge HCT was approved by the FDA in 2009 under NDA 022314 [1]. Orange Book analysis should separate the listed drug’s approval status from the remaining enforceability of individual patents.

For a generic applicant, the critical regulatory pathway is an ANDA with a Paragraph IV certification where an unexpired listed patent is challenged. The applicant must address:

• Each Orange Book-listed patent.
• The patent expiration date.
• Any pediatric exclusivity.
• The scope of the proposed label.
• Whether the ANDA product uses the same dosage form and route.
• Whether a method-of-use statement must be carved out.

A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act. The statutory 30-month stay may delay approval, although the timing depends on the patent listing, notice date, litigation and court decisions [3].

For mature products, the more significant issue is often whether any listed patent remains enforceable when the ANDA is filed. A generic sponsor should not rely solely on the historical product launch date. It should review the current FDA Orange Book, patent-family status, terminal disclaimers, maintenance fees, reexamination history and court outcomes.

When did Exforge HCT lose exclusivity?

FDA approval in 2009 did not itself establish a long period of market exclusivity for the triple combination. The product was approved with standard small-molecule regulatory exclusivity rather than biologic exclusivity. Any five-year new chemical entity exclusivity would not apply to a product whose active ingredients were previously approved.

The commercial exclusivity period was therefore driven primarily by patents, regulatory approval of generic versions and market uptake. The principal U.S. patent estate associated with the triple combination reached the end of its ordinary term in the 2020s, subject to patent-specific adjustments and extensions [2].

The practical result is that amlodipine/valsartan/hydrochlorothiazide is a generic-entry market in the United States and other major jurisdictions. Market access timing still depends on country-specific patent rights, local regulatory filings and the availability of approved generic products.

Which companies are challenging or competing with Exforge HCT?

Competition comes from several groups:

• Generic manufacturers filing ANDAs or equivalent applications.
• Regional pharmaceutical companies selling the combination outside the United States.
• Suppliers of the two-drug amlodipine/valsartan combination.
• Manufacturers of separate tablets prescribed together.
• Other triple antihypertensive combinations, including ARB/thiazide and calcium-channel-blocker/ARB products.

The commercial competitor is not limited to an identical triple tablet. Physicians may substitute separate amlodipine, valsartan and hydrochlorothiazide products where reimbursement, inventory or prescribing habits favor multiple tablets.

Generic competition is likely to be price-led after multiple approvals. Differentiation must come from reliable supply, broad strength coverage, packaging, tablet size, patient adherence and payer access.

What commercial opportunities exist in excipients and formulation?

Lower-cost generic platforms

The largest opportunity is a manufacturable formulation using widely available excipients and a short process. A direct-compression platform can reduce water use, drying time and manufacturing cost if powder flow and content uniformity are adequate.

Smaller and easier-to-swallow tablets

Valsartan drives tablet mass. A higher-density formulation using optimized granulation or compressible excipients may reduce tablet volume. This can improve adherence, particularly in older patients taking several chronic medicines.

Orally disintegrating or dispersible tablets

Amlodipine/valsartan/hydrochlorothiazide is a potential candidate for an orally disintegrating or dispersible product, although the high valsartan dose creates a significant tablet-size challenge. Taste masking, friability and moisture protection would require careful development.

Pediatric and geriatric presentations

Hypertension treatment in older adults creates demand for easy-to-swallow products. A scored tablet, smaller unit dose or dispersible formulation may have commercial value even without strong patent exclusivity.

Fixed-dose combinations for emerging markets

In markets with high hypertension prevalence and limited access to combination therapy, low-cost triple tablets can support volume growth. Local manufacturing, flexible packaging and climate-zone stability are important. Alu-Alu blister packaging may be justified in hot and humid regions, while high-barrier HDPE bottles can support larger commercial packs.

Excipient supply and co-development

Excipient manufacturers can create value through co-processed fillers, optimized disintegrant systems and low-moisture direct-compression platforms. The strongest opportunity is not ownership of a single excipient but a documented performance package that reduces development time and improves manufacturing reproducibility.

How does this product compare with other fixed-dose antihypertensives?

Product category	Commercial advantage	Formulation challenge
Amlodipine/valsartan	Two-pill substitution and broad use	Valsartan dissolution
Valsartan/hydrochlorothiazide	Established ARB/diuretic market	Dose uniformity and moisture
Amlodipine/valsartan/hydrochlorothiazide	Maximum pill-burden reduction	Larger tablet and complex bioequivalence
Separate tablets	Flexible dose titration	Lower adherence and higher pill burden
Other ARB/CCB/thiazide combinations	Therapeutic substitution	Different API and patent landscape

The triple combination has a clear adherence proposition, but the addressable market is narrower than the market for two-drug combinations. Patients must require all three mechanisms, and clinicians may prefer titrating components separately.

What generic launch risks exist for amlodipine/valsartan/hydrochlorothiazide?

The main risks are regulatory and operational rather than active-ingredient discovery risks.

• Failure to match dissolution for valsartan.
• Amlodipine content-uniformity failures.
• Large tablet size and poor patient acceptability.
• Stability failures in high humidity.
• Inadequate demonstration of bioequivalence across all three APIs.
• Patent litigation following a Paragraph IV certification.
• Price erosion after multiple generic launches.
• API supply disruption, particularly for valsartan.
• Nitrosamine or other impurity controls affecting valsartan supply and release testing.

The valsartan nitrosamine recall history showed that API supplier quality can affect entire combination products, even when the finished-tablet formulation is technically sound [4].

What is the patent strength of the formulation opportunity?

The legacy patent estate for the branded triple combination is materially weaker than a new chemical entity estate because the APIs are old and the product is an immediate-release combination. Patent strength is highest where claims cover a specific and non-obvious combination, dosage regimen, solid state, release profile or manufacturing process.

A routine substitution of crospovidone for croscarmellose sodium is unlikely to provide strong exclusion. A formulation with unexpected dissolution, stability or bioavailability advantages may support patent protection, but the evidence must be comparative and reproducible.

The best commercial strategy is usually:

1. Develop a low-cost bioequivalent core product.
2. Add a differentiated formulation only where it solves a documented patient or manufacturing problem.
3. Protect the differentiated version with formulation, process and use claims.
4. Avoid dependence on a narrow excipient patent for the base business.

Key Takeaways

• Amlodipine/valsartan/hydrochlorothiazide is a mature generic opportunity centered on Exforge HCT.
• Valsartan is the main formulation challenge because of solubility and dissolution sensitivity.
• Amlodipine requires disciplined pre-blending and segregation control.
• Microcrystalline cellulose, crospovidone, colloidal silicon dioxide and controlled magnesium stearate are practical starting points.
• Dry granulation or direct compression can reduce manufacturing cost and moisture exposure.
• The strongest commercial opportunities are low-cost generics, smaller tablets, dispersible presentations, regional packaging and reliable API supply.
• Historical combination patents, including U.S. Patent No. 7,585,865, should be assessed against current Orange Book listings and jurisdiction-specific patent status.
• Paragraph IV litigation risk depends on the patents listed when the ANDA is filed, not only on the original product approval date.
• Routine excipient substitution is unlikely to create durable exclusivity.
• A differentiated formulation needs measurable advantages in dissolution, stability, tablet size, adherence or manufacturing performance.

Frequently Asked Questions

Can valsartan be formulated with hydrochlorothiazide and amlodipine in one immediate-release tablet?

Yes. The commercial reference product demonstrates feasibility. Development must control valsartan dissolution, low-dose amlodipine uniformity, tablet size and release consistency.

Which excipient is most important for this triple combination?

No single excipient controls the product. The highest-impact choices usually involve the filler, disintegrant and lubricant system, together with valsartan particle-size control and the blending process.

Is a sustained-release version commercially attractive?

Potentially, but it would require new pharmacokinetic, formulation and regulatory work. The immediate-release product has a simpler regulatory pathway and lower manufacturing risk.

Can a generic manufacturer avoid all formulation patents by changing excipients?

No. A change in excipients may avoid a narrow claim, but it does not automatically avoid broad composition, dosage-regimen, process or method-of-use claims.

Is a co-processed excipient platform valuable for this product?

Yes, if it improves flow, content uniformity, compression, dissolution or stability while reducing process steps. Its value is strongest when the platform supports multiple fixed-dose antihypertensive products.

References

1. U.S. Food and Drug Administration. (2009). Exforge HCT prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,585,865: Pharmaceutical compositions comprising valsartan, amlodipine and hydrochlorothiazide. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2018). FDA updates and press announcements on valsartan impurities and recalls. FDA.